Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 3 | Cellular & Molecular Biology Letters

Fig. 3

From: Role of USP7 in the regulation of tolerogenic dendritic cell function in type 1 diabetes

Fig. 3

USP7 blockade decreases PD-L1 and PD-L2 expression in tolerogenic Stat5b-CA.DCs. Purified splenic DCs (1 × 105 cells/well) from NOD and NOD.Stat5b-CA mice were cultured for 24 h in the presence (+ P5091) or absence (− P5091) of USP7 inhibitor (5 µM/mL). DCs were washed, labeled with anti-CD11c mAbs in combination with anti-PD-L1 and anti-PD-L2 mAbs. AD Flow cytometry plots depict PD-L1 and PD-L2 expression (A, C) and cell frequencies (B, D) in CD11c+ DCs. E Flow cytometry histogram depicts levels of PD-L1 and PD-L2 expressions and (FG) MFI in CD11c+ DCs treated with or without USP7 inhibitor (5 µM/mL). Data are shown as the mean ± SEM of five independent experiments. One-way ANOVA followed by Tukey’s post hoc test was used. n.s, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001

Back to article page